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TroBACKGROUND Investigators have hypothesized that sodium-glucose cotransporter 2 (SGLT2) inhibitors exert diuretic
effects that contribute to their ability to reduce serious heart failure events, and this action is particularly important in
patients with fluid retention.
OBJECTIVES This study sought to evaluate the effects of the SGLT2 inhibitor empagliflozin on symptoms, health
status, and major heart failure outcomes in patients with and without recent volume overload.
METHODS This double-blind randomized trial compared the effects of empagliflozin and placebo in 3,730 patients with
heart failure and a reduced ejection fraction, with or without diabetes. Approximately 40% of the patients had volume
overload in the 4 weeks before study enrollment.
RESULTS Patients with recent volume overload were more likely to have been hospitalized for heart failure and to have
received an intravenous diuretic agent in an outpatient setting in the previous 12 months, and to experience a heart failure
event following randomization, even though theyweremore likely to be treatedwith high doses of a loop diuretic agent as an
outpatient (all p<0.001).When comparedwith placebo, empagliflozin reduced the composite risk of cardiovascular death or
hospitalization for heart failure, decreased total hospitalizations for heart failure, and improved health status and functional
class. Yet despite the predisposition of patients with recent volume overload to fluid retention, the magnitude of these
benefits (even after 1month of treatment) was notmoremarked in patients with recent volume overload (interaction p values
>0.05). Changes inbodyweight, hematocrit, and natriuretic peptides (eachpotentially indicative of a diuretic actionof SGLT2
inhibitors) did not track each other closely in their time course or in individual patients.
CONCLUSIONS Taken together, study findings do not support a dominant role of diuresis in mediating the
physiological changes or clinical benefits of SGLT2 inhibitors on the course of heart failure in patients with a reduced
ejection fraction. (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction
[EMPEROR-Reduced]; NCT03057977) (J Am Coll Cardiol 2021;77:1381–92) © 2021 The Authors. Published by Elsevier
on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license
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1382T he action of sodium-glucosecotransporter 2 (SGLT2) inhibitorsto promote natriuresis and osmotic
diuresis (1–4) has been proposed as a central
mechanism by which these drugs reduce
heart failure hospitalizations in large-scale
trials (5–7). Sodium retention in patients
with heart failure is related to increased so-
dium reabsorption in the proximal tubule
(8), and by attenuating the sodium reabsorp-
tion at this site, SGLT2 inhibitors may poten-
tiate the effect of diuretic agents acting atthe loop of Henle (2,9,10). The effects of SGLT2 inhib-
itors to increase hematocrit and decrease body weight
and circulating natriuretic peptides (6,7) have been
linked by some investigators to an effect of diuresis
to contract plasma and extracellular volume (11–13).
However, the actions of SGLT2 inhibitors on these
biomarkers can be explained by mechanisms that
are independent of sodium and water excretion
(14–17).SEE PAGE 1393It has been proposed that if a diuretic action of
SGLT2 inhibitors leads to a reduction in heart failure
events, such a benefit would be particularly manifest
in patients with heart failure who have fluid retention
as a major feature of their history and clinical course
(18,19). Typically, these patients manifest ongoing
episodes of edema and other signs of organ conges-
tion and volume overload, experience worse symp-
toms and clinical instability, and require repeated
outpatient and inpatient interventions, especially the
intensification of therapy with diuretic agents (20,21).
This unfavorable course is often seen despite the use
of high maintenance doses of oral diuretic agents, a
finding suggesting a state of diuretic resistance
(21,22). By acting on sodium reabsorption in the
proximal tubule, SGLT2 inhibitors are poised to
overcome resistance to loop diuretic agents that act
more distally (23).
If the ability of SGLT2 inhibitors to potentiate the
effect of loop diuretic agents is important, then pa-
tients who experience recent or repeated episodes of
volume overload may be particularly likely to show alasgow, United Kingdom; iBoehringer Ingelheim International
, University of Heidelberg, Mannheim, Germany; kBoehringer Inge
he lBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Ger
s attest they are in compliance with human studies committe
and Food and Drug Administration guidelines, including patien
thor Center.
received December 28, 2020; revised manuscript received Januareduction in heart failure events during long-term
treatment with SGLT2 inhibitors. This hypothesis
was specifically tested in a secondary analysis of the
EMPEROR-Reduced (EMPagliflozin outcomE tRial in
Patients With chrOnic heaRt Failure With Reduced
Ejection Fraction) trial, which evaluated the efficacy
and safety of empagliflozin in patients with heart
failure and a reduced ejection fraction.
METHODS
The design of the EMPEROR-Reduced trial has been
described previously (8). Ethics approval was ob-
tained at each study site, and all patients provided
informed consent; the registration identifier at Clin-
icalTrials.gov is NCT03057977.
Participants had New York Heart Association
(NYHA) functional class II to IV heart failure and an
ejection fraction #40%, and they were receiving all
appropriate treatments for heart failure. We prefer-
entially enrolled patients with an ejection fraction
of #30% by requiring those patients with higher
ejection fractions to have been hospitalized for heart
failure within 12 months or to have markedly
increased levels of N-terminal pro–B-type natriuretic
peptide (NT-proBNP) (i.e.,$1,000 pg/ml or$2,500 pg/
ml in patients with an ejection fraction of 31% to 35%
or 36% to 40%, respectively); these thresholds were
doubled in patients with atrial fibrillation. All patients
were recruited as outpatients, but they were excluded
if they had acute decompensation or a change in
diuretic agents within 1 week before study enrollment.
Before randomization, investigators identified
patients who had clinical evidence of volume
overload in the 4 weeks before the first study visit
and distinguished them from those patients who
had been clinically euvolemic or volume depleted.
Because there is no consensus on the definition of
euvolemia, no guidance was provided to in-
vestigators on how to identify patients with volume
overload. We assessed the baseline use of diuretic
agents, and patients were categorized as receiving
high or low doses of a loop diuretic agent, with the
former defined as >40 mg daily of furosemide or
its equivalent (24).GmbH, Ingelheim, Germany; jFaculty of Medicine
lheim Pharmaceuticals, Inc., Ridgefield, Connecticut,
many.
es and animal welfare regulations of the authors’
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ry 14, 2021, accepted January 15, 2021.
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1383Patients were randomized and double blinded (in a
1:1 ratio) to receive placebo or empagliflozin 10 mg
daily, in addition to their usual therapy for heart
failure. Following randomization, all treatments for
heart failure or other medical conditions could be
initiated or altered at the discretion of the investi-
gator. Patients were periodically assessed for major
outcomes and functional capacity related to heart
failure, intensification of diuretic therapy, vital signs,
heart failure–pertinent biomarkers, and adverse
events.
The primary endpoint was the composite of car-
diovascular death or hospitalization for heart failure,
analyzed as time to first event. The first secondary
endpoint was the occurrence of all (first and recurrent)
hospitalizations for heart failure. The second second-
ary endpoint was the slope of the change in estimated
glomerular filtration rate (eGFR) during double-blind
treatment. Serious adverse renal outcomes included
long-term dialysis, renal transplantation, a sustained
eGFR reduction of $40%, or a sustained eGFR <15 ml/
min/1.73 m2 (if baseline eGFR was $30) or a sustained
eGFR <10 ml/min/1.73 m2 (if baseline eGFR was <30).
Additional analyses included the following: 1) time to
reported intensification of therapy with diuretic
agents; 2) changes in the Kansas City Cardiomyopathy
Questionnaire at 12 and 52 weeks; and 3) changes in
NYHA functional class, hematocrit, uric acid, NT-
proBNP, body weight, systolic blood pressure, serum
sodium, and serum albumin at 4 and 52 weeks.
OUTCOME MEASURES AND STATISTICAL ANALYSIS.
For time-to-first-event analyses, between-group
differences were assessed using a Cox proportional
hazards model, with pre-specified covariates of age,
sex, region, diabetes, ejection fraction, and eGFR at
baseline. For the analysis of total events, between-
group differences were assessed using a joint frailty
model, with cardiovascular death as a competing risk,
and changes in NYHA functional class were evaluated
by logistic regression. Both analyses used the same
covariates as the time-to-first event analyses and
included baseline NYHA functional class for the anal-
ysis of NYHA functional class. The eGFR slope analysis
was determined on the basis of on-treatment data us-
ing a random coefficient model, with age and baseline
eGFR as linear covariates and sex, region, ejection
fraction, diabetes, baseline eGFR, time, and recent
volume overload interaction terms as fixed effects.
For vital signs and laboratory measurements,
treatment effects were assessed using a mixed model
for repeated measures, with age and baseline eGFR as
linear covariates and baseline score by visit, visit by
treatment, sex, region, ejection fraction, individuallast projected visit, and diabetes as fixed effects. All
analyses of changes in NT-proBNP were performed on
log-transformed data.
Interaction p values were used to compare the
magnitude of the effect of empagliflozin on pre-
specified outcomes in groups defined by the pres-
ence or absence of recent volume overload. To assess
differences in the course of the patients with or
without recent volume overload at baseline, analyses
were performed on placebo recipients only, by using
the same covariate adjustments.
RESULTS
Of the 3,730 randomized patients, 1,477 patients
(39.6%) had volume overload in the previous 4 weeks.
A total of 2,128 patients were reported to have been
euvolemic for the entire previous 4 weeks, and 121
had experienced volume depletion; these 2,249 pa-
tients were grouped together and were considered to
have had no recent volume overload. Four patients
with missing data for volume overload are not
considered in this report.
CLINICAL CHARACTERISTICS AND CLINICAL
COURSE. The baseline characteristics of the patients
with or without recent volume overload were similar
with respect to ejection fraction and eGFR, but pa-
tients with recent volume overload weremore likely to
have a history of hypertension, diabetes, and atrial
fibrillation. Patients with recent volume overloadwere
also more likely to have had worsening NYHA func-
tional class within 3months, to have been hospitalized
for heart failure and to have received an intravenous
diuretic agent as an outpatient within the previous
12 months, and to have NYHA functional class III or IV
symptoms at randomization (all p <0.0001). Further-
more, patients with recent volume overload had
higher serum levels of NT-proBNP, even though they
were more likely to be receiving high doses of a loop
diuretic agent (both p <0.0001). The 2 groups were
similar with respect to the use of beta-blockers and
mineralocorticoid receptor antagonists, but patients
with recent volume overload were less likely to have
undergone implantable cardioverter-defibrillator or
cardiac resynchronization therapy (all p <0.0001).
Serum chloride was lower in patients with recent vol-
ume overload; other baseline characteristics are
shown in Table 1. Of note, patients recruited in Asia or
who were of Asian descent were more likely to have
recent volume overload.
Despite similarities in ejection fraction, renal
function, and the use of neurohormonal antagonists,
when treated with placebo, patients with recent
TABLE 1 Baseline Characteristics of Patients With or Without Recent Volume Overload at Baseline
Patients Without Recent
Volume Overload (n ¼ 2,249)
Patients With Recent










Age, yrs 66.4  11.2 66.7  10.8 66.6  11.3 67.9  10.8 0.088
Women 280 (25.2) 282 (24.8) 174 (23.1) 155 (21.4) 0.058
Race
White 781 (70.4) 813 (71.4) 522 (69.2) 511 (70.7) <0.001
Black 76 (6.8) 74 (6.5) 58 (7.7) 49 (6.8)
Asian 178 (16.0) 189 (16.6) 157 (20.8) 148 (20.5)
Region
North America 145 (13.1) 149 (13.1) 68 (9.0) 62 (8.6) <0.001
Latin America 385 (34.7) 390 (34.2) 259 (34.4) 251 (34.7)
Europe 399 (35.9) 414 (36.3) 276 (36.6) 262 (36.2)
Asia 123 (11.1) 122 (10.7) 122 (16.2) 126 (17.4)
Clinical course of heart failure
Duration of heart failure, yrs 4.4 (1.7, 9.2) 3.8 (1.5, 8.7) 3.7 (1.3, 8.8) 3.8 (1.2, 8.8) 0.431
NYHA functional class III–IV 221 (19.9) 243 (21.3) 244 (32.4) 221 (30.6) <0.001
Worsening NYHA functional class within 3 months 36 (3.2) 37 (3.2) 92 (12.2) 67 (9.3) <0.001
Hospitalization for HF within 12 months 282 (25.4) 293 (25.7) 291 (38.6) 283 (39.1) <0.001
Outpatient IV diuretic agents within 12 months 123 (11.1) 124 (10.9) 129 (17.1) 117 (16.2) <0.001
Body mass index, kg/m2 27.7  5.1 27.8  5.3 28.0  5.6 28.2  5.7 0.055
LV ejection fraction, % 27.1  5.9 27.8  5.8 27.4  6.4 27.6  6.2 0.747
Systolic blood pressure, mm Hg 121.6  15.5 122.2  15.7 121.1  15.1 123.1  16.2 0.741
Heart rate, beats/min 71.0  11.3 70.3  11.5 72.4  12.4 72.0  11.9 <0.001
NT-proBNP, pg/ml 1,772 (1,074–3,155) 1,805 (1,032–3,191) 2,079 (1,256–4,002) 2,045 (1,152–3,934) <0.001
Serum sodium, mEq/l 140.7  2.9 140.6  3.1 140.4  3.1 140.6  3.1 0.255
Serum chloride, mEq/l 100.8  3.5 100.9  3.7 100.4  3.8 100.6 3.9 0.004
Estimated GFR, ml/min/1.73 m2 62.6  21.3 62.0  21.4 61.6  22.0 61.6  22.3 0.358
Cardiovascular history
Hypertension 796 (71.7) 801 (70.3) 551 (73.1) 547 (75.7) 0.026
Previous myocardial infarction 491 (44.2) 535 (47.0) 292 (38.7) 303 (41.9) 0.001
Atrial fibrillation or atrial flutter 416 (37.5) 414 (36.3) 321 (42.6) 288 (39.8) 0.006
Diabetes mellitus 528 (47.6) 545 (47.8) 400 (53.1) 382 (52.8) 0.002
Treatment of heart failure
High doses of loop diuretic agents 223 (20.1) 219 (19.2) 196 (26.0) 191 (26.4) <0.001
Beta-blocker 1,053 (94.9) 1,078 (94.6) 712 (94.4) 687 (95.0) 0.964
Mineralocorticoid receptor antagonist 793 (71.4) 797 (70.0) 560 (74.3) 508 (70.3) 0.288
Neprilysin inhibitor 249 (22.4) 219 (19.2) 137 (18.2) 121 (16.7) 0.012
Cardiac glycosides 186 (16.8) 177 (15.5) 125 (16.6) 106 (14.7) 0.683
Implantable cardioverter-defibrillator* 396 (35.7) 391 (34.3) 195 (25.9) 186 (25.7) <0.001
Cardiac resynchronization therapy† 145 (13.1) 156 (13.7) 77 (10.2) 64 (8.9) <0.001
Values are mean  SD, n (%), or median (interquartile range). The p values refer to the difference between patients with or without recent volume overload, combining the 2 randomized treatment groups.
Patients who self-identified with $1 race or with no race are classified as “other”; data for “other” or missing for both race and region are not shown. *Implantable cardioverter-defibrillator with or without
cardiac resynchronization therapy. †Cardiac resynchronization therapy with or without a defibrillator.
GFR ¼ glomerular filtration rate; HF ¼ heart failure; IV ¼ intravenous; LV ¼ left ventricular; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association.
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1384volume overload were more likely to experience the
composite endpoint of cardiovascular death or hos-
pitalization for heart failure (hazard ratio [HR]: 1.31;
95% confidence interval [CI]: 1.09 to 1.57; p ¼ 0.0044)
and had a higher number of total hospitalizations for
heart failure (HR: 1.36; 95% CI: 1.06 to 1.75; p ¼ 0.016).
Additionally, when treated with placebo, patients
with recent volume overload were more likely than
those without recent volume overload to requireintensification of treatment with diuretic agents
following randomization (HR: 1.22; 95% CI: 1.00 to
1.48; p ¼ 0.047).
EFFECT ON HEART FAILURE AND RENAL OUTCOMES.
When compared with placebo, empagliflozin reduced
the combined risk of cardiovascular death or
hospitalization for heart failure in patients with
and without recent volume overload (HR: 0.81;
95% CI: 0.66 to 0.99 and HR: 0.71; 95% CI: 0.58 to
CENTRAL ILLUSTRATION Effect of Empagliflozin on the Combined Risk of Cardiovascular Death or Hospitalization
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Cumulative incidence plots, with hazard ratio (HR), 95% confidence interval (CI), and p value for the comparison of empagliflozin and placebo. Interaction p value for
the difference in the effect of empagliflozin on the left and right is 0.34.
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13850.86, respectively; interaction p ¼ 0.34) (Central
Illustration, Table 2). The effect of empagliflozin to
reduce the total number of hospitalizations for heart
failure was somewhat less compelling in patients
with as compared with patients without recent vol-
ume overload (16% vs. 40% risk reduction, respec-
tively; HR: 0.84; 95% CI: 0.63 to 1.12 and HR: 0.60;
95% CI: 0.47 to 0.78;, respectively; interaction
p ¼ 0.09) (Figure 1 and Table 2). For these endpoints,
the incidence plots separated immediately in patients
without recent volume overload, but this separation
occurred after 30 to 45 days in the patients with
recent volume overload.
When compared with placebo, empagliflozin
slowed the rate of decline in eGFR in patients with
and without recent volume overload to a similar de-
gree. Similarly, empagliflozin reduced the risk of a
serious adverse renal outcome in patients with and
without recent volume overload HRs of 0.49 (95% CI:
0.26 to 0.92) and 0.51 (95% CI: 0.27 to 0.91), respec-
tively (Table 2), with no difference between the vol-
ume overload subgroups (interaction p ¼ 0.95). The
influence of recent volume overload on other
outcome measures is summarized in Table 2.
EFFECT ON USE OF DIURETIC AGENTS, HEALTH
STATUS AND FUNCTIONAL CLASS. When compared
with the placebo group, patients in the empagliflozin
group were less likely to require intensification oftreatment with diuretic agents, with an HR of 0.68
(95% CI: 0.55 to 0.85) in the patients with recent
volume overload and an HR of 0.67 (95% CI: 0.55 to
0.82) in the patients without recent volume overload
(interaction p ¼ 0.88) (Figure 2, Table 2). Empagli-
flozin improved the Kansas City Cardiomyopathy
Questionnaire clinical summary score at 12 weeks to a
similar degree in patients with and without recent
volume overload (interaction p ¼ 0.65); these benefits
were sustained during double-blind therapy in both
volume-defined subgroups.
For changes in NYHA functional class at 4 weeks,
empagliflozin-treated patients had a higher odds of
showing improvement, odds ratios of 1.43 (95% CI:
1.04 to 1.97) and 1.34 (95% CI: 0.99 to 1.82) for pa-
tients with or without recent volume overload,
respectively. At this time, empagliflozin-treated pa-
tients also had a lower odds of showing worsening
NYHA functional class, with odds ratios of 0.79
(95% CI: 0.41 to 1.54) and 0.50 (95% CI: 0.29 to 0.85)
with and without recent volume overload, respec-
tively. For both improvement and worsening, the
responses to empagliflozin in the 2 volume overload
groups did not differ (interaction p ¼ 0.78 and
p ¼ 0.29, respectively). Similar patterns were seen for
changes in functional class at 52 weeks (Table 2).
EFFECT ON VITAL SIGNS, BIOMARKERS, AND
SAFETY. As compared with placebo, NT-proBNP
TABLE 2 Effects of Empagliflozin in Patients With or Without Recent Volume Overload at Baseline
Outcomes
Patients Without Recent Volume
Overload (n ¼ 2,249)
Patients With Recent Volume











Cardiovascular death or adjudicated hospitalization
for heart failure
246 (22.2) 182 (16.0) 214 (28.4) 179 (24.8) 0.34
0.71 (0.58–0.86), p ¼ 0.0004 0.81 (0.66–0.99), p ¼ 0.035
Total (first and recurrent adjudicated
hospitalizations for heart failure)
275 181 274 207 0.09
0.60 (0.47–0.78), p ¼ 0.0002 0.84 (0.63–1.12), p ¼ 0.24
Slope of decline in eGFR (ml/min/1.73 m2/yr) 2.1  0.3 0.6  0.3 2.6  0.4 0.5  0.3 0.38
þ1.49  0.42, p ¼ 0.0005 þ2.06  0.50, p < 0.0001
Composite of serious adverse renal outcomes 28 (2.5) 15 (1.3) 30 (4.0) 15 (2.1) 0.95
0.51 (0.27–0.95), p ¼ 0.034 0.49 (0.26–0.92), p ¼ 0.025
Time to first adjudicated hospitalization for heart
failure
185 (16.7) 123 (10.8) 155 (20.6) 123 (17.0) 0.24
0.63 (0.50–0.80), p < 0.0001 0.77 (0.61–0.98), p ¼ 0.033
Cardiovascular death 104 (9.4) 93 (8.2) 98 (13.0) 94 (13.0) 0.71
0.89 (0.67–1.17), p ¼ 0.40 0.96 (0.72–1.27), p ¼ 0.76
Patients requiring intensification of diuretic
agents (time-to-event-analysis)
224 (20.2) 160 (14.0) 188 (24.9) 137 (18.9) 0.88
0.67 (0.55–0.82), p ¼ 0.0001 0.68 (0.55–0.85), p ¼ 0.0008
NYHA functional class at 4 weeks
Odds ratio for improvement 1.34 (0.99–1.82), p ¼ 0.055 1.43 (1.04–1.97), p ¼ 0.028 0.78
Odds ratio for worsening 0.50 (0.29–0.85), p ¼ 0.0098 0.79 (0.41–1.54), p ¼ 0.49 0.29
NYHA functional class at 52 weeks
Odds ratio for improvement 1.25 (0.96–1.64), p ¼ 0.10 1.44 (1.06–1.95), p ¼ 0.02 0.51
Odds ratio for worsening 0.51 (0.31–0.85), p ¼ 0.01 0.81 (0.46–1.43), p ¼ 0.47 0.23
KCCQ clinical summary score at 12 weeks þ1.74 (0.47–3.01), p ¼ 0.007 þ2.21 (0.64–3.78), p ¼ 0.006 0.65
KCCQ clinical summary score at 52 weeks þ1.16 (–0.42–2.75), p ¼ 0.15 þ2.32 (0.38–4.26), p ¼ 0.019 0.37
Values are n (%), mean  SD, HR (95% CI), unless otherwise indicated. For NYHA functional class, a benefit of empagliflozin is indicated by odds ratios >1.0 for improvement and <1.0 for worsening.
CI ¼ confidence interval; eGFR ¼ estimated glomerular filtration rate; HR ¼ hazard ratio; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; other abbreviations as in Table 1.
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1386declined in the empagliflozin-treated group,
modestly after 4 weeks and to a greater degree after
52 weeks, but these decreases were not influenced by
the presence or absence of recent volume overload
(interaction p ¼ 0.38 and p ¼ 0.67, respectively)
(Table 3). Systolic blood pressure declined by a mean
of 1 to 2 mm Hg after 4 weeks, and it decreased by 0 to
1 mm Hg after 52 weeks, without an effect of recent
volume overload (interaction p ¼ 0.17 and p ¼ 0.51,
respectively). Body weight declined by w1.0 kg
throughout double-blind treatment, but it decreased
similarly in patients with and without recent volume
overload. Empagliflozin increased hematocrit after
4 weeks and 52 weeks, and this effect did not vary
according to volume overload. Treatment with
empagliflozin was accompanied by very small in-
creases in serum albumin without changes in serum
sodium, with similar effects in the volume overload
groups (Table 3). Importantly, changes in body weight
were poorly correlated with changes in NT-proBNP or
with changes in hematocrit in individual patientstreated with empagliflozin (r ¼ 0.12 and r ¼ 0.17,
respectively, at 4 weeks; and r ¼ 0.14 and r ¼ 0.045,
respectively, at 52 weeks).
Additionally, the frequency of reports of adverse
events related to symptomatic hypotension, volume
depletion, or worsening renal function was not
increased by empagliflozin, either in patients with or
without recent volume overload. The incidence of
volume depletion was somewhat higher and the
incidence of hyperkalemia somewhat lower in
empagliflozin-treated patients with recent volume
overload (Supplemental Table 1), but the between-
group differences in the number of events were small.
DISCUSSION
Patients who had volume overload in the 4 weeks
before enrollment in the EMPEROR-Reduced trial had
a history of clinical instability and remained at
elevated risk for heart failure events during follow-
up. Patients with recent volume overload were
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p value for the difference in the effect of empagliflozin on the left and right is 0.09.
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1387likely to have been hospitalized for heart failure and
to have received an intravenous diuretic agent as an
outpatient within the previous 12 months, to have
worsening NYHA functional class within 3 months,
and to have class III to IV symptoms at the time of
randomization. These patients were also more likely
to experience the composite endpoint of cardiovas-
cular death or hospitalization for heart failure. These
clinical features were apparent even though these
patients were more likely to have received high doses
of a loop diuretic agent as an outpatient and to
require intensification of diuretic therapy following
randomization, thus indicating a degree of diuretic
resistance, a finding supported by the lower values of
serum chloride in these patients (25). The predispo-
sition of these patients to fluid retention and clinical
instability could not be explained by ejection frac-
tion, systolic blood pressure, or renal function.
Interestingly, patients with recent volume overload
represented 40% of the patients in the trial, which
was specifically enriched for those patients with
markedly elevated levels of natriuretic peptides (6).
SGLT2 inhibitors may potentiate the effects of
loop diuretic agents, and it has been proposed that
these drugs are particularly effective in promoting
fluid excretion in patients with volume overload
before treatment (2,9,10,18,19). However, in the
EMPEROR-Reduced trial, empagliflozin reduced the
combined risk of cardiovascular death or hospitali-
zation for heart failure in patients with and without
recent volume overload, with no difference betweenthe 2 groups. In fact, the effect of empagliflozin to
reduce the total number of hospitalizations for heart
failure was somewhat less compelling in patients
with recent volume overload as compared with pa-
tients without recent volume overload (16% vs. 40%
risk reduction, respectively), and for both endpoints,
the benefits of empagliflozin seemed to emerge more
rapidly in patients without recent volume overload.
In parallel with the benefits on the course of heart
failure, empagliflozin reduced the need for intensi-
fication of diuretic agents and improved Kansas City
Cardiomyopathy Questionnaire and NYHA functional
class, but the magnitude of these benefits was
similar in patients with or without recent volume
overload.
In some mechanistic studies, SGLT2 inhibitors
have been reported to produce changes in urinary
sodium, glucose, and water excretion and decreases
in plasma volume within the first several days of
treatment (1–4). In other reports, however, meaning-
ful changes in urinary volume, sodium excretion, or
extracellular fluid have not been seen acutely (even
in acute heart failure), and if present, these changes
have not necessarily been sustained after 1 to 2 weeks
(2,3,10,13,16,26–28). SGLT2 inhibitors do not have an
immediate effect to reduce circulating natriuretic
peptides or to alter the dose of diuretic agents used
for the treatment of heart failure in most patients
(24,28–31). In the current study, treatment with
empagliflozin did not change serum sodium values
and produced very small increases in serum albumin.
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value for the difference in the effect of empagliflozin on the left and right is 0.88. HR ¼ hazard ratio.
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the use of SGLT2 inhibitors in type 2 diabetes (32),
and it is likely related to reactive changes in the
nonerythrocyte component of blood volume that
follow any drug-induced increases in red blood cell
mass (32,33).
Despite these observations, it is possible that
diuretic effects could have occurred before our
week 4 assessments, and even if transient, they
could conceivably have contributed to the short-
term benefits of these drugs. In our trial, the ef-
fects of empagliflozin to improve NYHA functional
class and to reduce the risk of hospitalizations for
heart failure were statistically significant within 12
to 28 days and were accompanied by a decrease in
body weight (34). Theoretically, a diuretic effect
could explain these early benefits, even if non-
diuretic mechanisms are responsible for the favor-
able effects seen during longer-term treatment.
However, in the current study, these early effects
on NYHA functional class, body weight, and heart
failure events were not more apparent in patients
with recent volume overload. Furthermore, neither
patients with nor without recent volume overload
had early effects on symptoms and heart failure
hospitalizations accompanied by an important
decrease in circulating natriuretic peptides. These
observations do not support a role for a short-term
diuretic effect in mediating the early benefits of
SGLT2 inhibitors on functional class or on heart
failure outcomes.Our observations also raise questions about the
role of diuresis in mediating changes in body
weight, hematocrit, and natriuretic peptides during
treatment with SGLT2 inhibitors. The time course of
changes in body weight did not closely parallel
changes in natriuretic peptides or hematocrit. When
treatment continued beyond 4 weeks, body weight
did not decline further, even though hematocrit
continued to increase and NT-proBNP continued to
decrease. Changes in body weight were poorly
correlated with changes in NT-proBNP or with
changes in hematocrit in individual patients treated
with empagliflozin, both after 4 weeks and after
52 weeks. It therefore seems likely that the effects
of SGLT2 inhibitors on these physiological measures
are explicable by nondiuretic actions of these drugs.
The decline in body weight appears to be related to
the loss of calories in the urine as a result of renal
glycosuria (16,17,35). The increase in hematocrit is
preceded by an increase in erythropoietin and
reticulocytosis (36,37), presumably related to
enhanced signaling of upstream regulators of
erythropoietin synthesis (14,38,39). Finally, the ef-
fect of SGLT2 inhibitors to decrease natriuretic
peptides is primarily seen after many months of
treatment, a finding suggesting that it reflects the
favorable effects of SGLT2 inhibitor on left ventric-
ular remodeling rather than the consequence of a
diuretic action (40).
STUDY STRENGTHS AND LIMITATIONS. The findings
of the current study should be viewed in light of its
TABLE 3 Changes in Vital Signs and Biomarkers in Patients Randomized to Placebo and Empagliflozin, According to Recent History of Volume Overload at Baseline
Patients Without Recent Volume
Overload (n ¼ 2,249)
Patients With Recent Volume













At 4 weeks 0.93 (0.90–0.97) 0.90 (0.87–0.93) 0.90 (0.86–0.94) 0.84 (0.80–0.88) 0.38
0.96 (0.92–1.01), p ¼ 0.14 0.93 (0.88–0.99), p ¼ 0.02
At 52 weeks 0.91 (0.86–0.97) 0.79 (0.74–0.83) 0.78 (0.72–0.83) 0.69 (0.64–0.74) 0.67
0.86 (0.79-0.94), p ¼ 0.0004 0.89 (0.80-0.98), p ¼ 0.017
Systolic blood pressure, mm Hg
At 4 weeks –2.1  0.4 –3.1  0.4 –0.8  0.5 –2.9  0.5 0.17
–1.0  0.6 (p ¼ 0.086) –2.2  0.7 (p ¼ 0.0017)
At 52 weeks –2.3  0.5 –2.7  0.5 –0.5  0.6 –1.7  0.6 0.51
–0.4  0.7 (p ¼ 0.61) –1.1  0.9 (p ¼ 0.20)
Body weight, kg
At 4 weeks þ0.16  0.09 –0.59  0.09 þ0.02  0.11 –0.61  0.11 0.53
–0.75  0.12 (p < 0.0001) –0.63  0.15 (p < 0.0001)
At 52 weeks –0.08  0.17 –0.76  0.17 þ0.32  0.21 –0.69  0.21 0.39
–0.68  0.24 (p ¼ 0.0045) –1.00  0.29 (p ¼ 0.0006)
Hematocrit, %
At 4 weeks –0.57  0.08 þ0.49  0.08 –0.68  0.10 þ0.67  0.10 0.11
þ1.06  0.11 (p < 0.0001) þ1.34  0.14 (p < 0.0001)
At 52 weeks –0.46  0.13 þ1.89  0.13 –0.27  0.16 þ2.11  0.16 0.92
þ2.35  0.18 (p < 0.0001) þ2.80  0.22 (p < 0.0001)
Serum sodium, mEq/l
At 4 weeks 0.0  0.1 –0.1  0.1 0.0  0.1 –0.3  0.1 0.39
–0.1  0.1 (p ¼ 0.45) –0.2  0.1 (p ¼ 0.084)
At 52 weeks –0.2  0.1 –0.1  0.1 –0.1  0.1 0.0  0.1 0.94
þ0.1  0.1 (p ¼ 0.30) þ0.1  0.2 (p ¼ 0.46)
Serum albumin, g/dl
At 4 weeks –0.03  0.01 þ0.01  0.01 –0.04  0.01 þ0.03  0.01 0.13
þ0.04  0.01 (p ¼ 0.0002) þ0.07  0.01 (p < 0.0001)
At 52 weeks –0.03  0.01 0.00  0.01 þ0.01  0.01 þ0.04  0.01 0.79
þ0.04  0.01 (p ¼ 0.016) þ0.03  0.02 (p ¼ 0.10)
Values are hazard ratio (95% confidence interval) or mean  SD. Because of the exceptional non-normal distribution, changes in NT-proBNP are shown as the ratio of adjusted geometric means and 95%
confidence intervals.
NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide.
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1389strengths and limitations. Because there are no
accepted criteria for defining euvolemia in the clinical
setting, site investigators relied on their judgment to
identify patients with volume overload. Despite the
subjective nature of this assessment, these physicians
correctly identified a group of patients who were
more likely to have had fluid retention and clinical
instability in the previous year and who were likely to
require diuretic therapy intensification and experi-
ence worsening heart failure events following
randomization. However, we did not perform base-
line or sequential measurements of plasma or extra-
cellular volume or assess changes in urinary sodium
or water excretion in our patients. Such measure-
ments are typically carried out in small, short-term,
mechanistic studies conducted under highly
controlled conditions where dietary salt and watercan be closely monitored and standardized. Yet small
mechanistic studies cannot ascertain long-term ef-
fects or determine whether physiological changes
produced by a drug are related to changes in the risk
of subsequent heart failure events.
Some investigators might suggest that patients with
recent volume overload had heart disease that was too
advanced to respond favorably to any drug interven-
tion. However, as compared with euvolemic patients,
patients with recent volume overload did not have
lower ejection fractions or systolic blood pressure or
worse renal function. Furthermore, patients with
advanced symptoms of heart failure respond as
favorably (if not more favorably) to angiotensin-
converting enzyme inhibitors, beta-blockers, and
mineralocorticoid receptor antagonists, as compared
with patients with less functional disability (39).
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1390Interestingly, in the EMPEROR-Reduced trial, patients
with an ejection fraction of 30% or less were particu-
larly responsive to treatment with empagliflozin with
respect to the effects on the risk of cardiovascular
death and hospitalizations for heart failure (6).
Finally, some investigators have hypothesized that
SGLT2 inhibitors act preferentially to reduce the
accumulation of fluid in the interstitial space (5), an
action that would not be readily discerned by mea-
surements of weight or blood constituents. However,
this mechanism has been based on modeling analyses
and not on direct measurements of interstitial fluid.
Furthermore, it is not clear how an effect of SGLT2
inhibitors on the proximal renal tubule could achieve a
selective effect to reduce the interstitial fluid volume,
especially when changes in the urinary excretion of
sodium or water are modest (2,3,10,13,16,26–28). In the
current analysis, investigators judged the volume of
interstitial fluid by the clinical assessment of circula-
tory overload, tissue congestion, and peripheral
edema. Previous studies have suggested that patients
with expanded extracellular volume are particularly
responsive to the diuretic effect of SGLT2 inhibitors
(18,19), and thus, we anticipated that patients with
volume overload would show a particular benefit with
these drugs; however, our findings did not confirm this
hypothesis. Of course, it is possible that patients who
are resistant to the actions of a loop diuretic agent are
also resistant to the action of a SGLT2 inhibitor on the
proximal tubule. However, the presence of diuretic
resistance at multiple renal tubular sites is typically
seen in patients with meaningful renal impairment; in
contrast, our patients with and without recent volume
overload did not differ with respect to baseline renal
function or with respect to changes in renal function
during follow-up.
CONCLUSIONS
Patients with heart failure whose clinical course is
characterized by episodes of volume overload despite
the use of loop diuretic agents are not more likely to
respond favorably to empagliflozin with respect to
symptoms, functional capacity, health status, or the
risk of hospitalizations for heart failure. Such patients
do not exhibit an exaggerated benefit with SGLT2
inhibitors, even during short-term treatment. Short-
and long-term changes in body weight are poorly
correlated with changes in natriuretic peptides or
hematocrit. These observations do not negate the
possibility that SGLT2 inhibitors may exert effects on
urine volume or composition or on fluidcompartments in the body. However, taken together,
our findings do not support a dominant role of
diuresis in mediating the physiological changes or
clinical benefits of SGLT2 inhibitors on the course of
heart failure in patients with a reduced ejection
fraction.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In pa-
tients with reduced left ventricular ejection fraction, ac-
tions other than the diuretic effects of SGLT2 inhibitors
are the predominant mediators of reduced hospitaliza-
tions for heart failure.
TRANSLATIONAL OUTLOOK: Future studies should
focus on effects of SGLT2 inhibitors other than urinary
sodium excretion and plasma volume, such as promotion
of nutrient deprivation signaling.
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